High throughput targeted gene sequencing in 738 Myelodysplastic Syndromes patients reveals novel oncogenic genes, rare driver mutations and complex molecular signatures with potential impact for patient diagnosis and prognosis in the clinic

Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, Sudhir Tauro, Gunes Gundem, Peter Van Loo, Andrea Pellagatti, Michael J. Groves, Nick C. P. Cross, Carlo Gambacorti-Passerini, Anthony R. Green, Jacqueline Boultwood, Paresh Vyas, Eva Hellstrom-Lindberg, David Bowen, Mario Cazzola, Michael R. Stratton, Peter Campbell

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Article numberLBA-5
Number of pages2
JournalBlood
Volume120
Issue number21
Publication statusPublished - 16 Nov 2012
Event54th Annual Meeting and Exposition of the American Society of Hematology - Georgia World Congress Center, Atlanta, United States
Duration: 8 Dec 201211 Dec 2012
http://www.isth.org/event/id/254548/54th-Annual-Meeting-and-Exposition-of-the-American-Society-of-Hematolo.htm

Cite this

Papaemmanuil, E., Gerstung, M., Malcovati, L., Tauro, S., Gundem, G., Van Loo, P., Pellagatti, A., Groves, M. J., Cross, N. C. P., Gambacorti-Passerini, C., Green, A. R., Boultwood, J., Vyas, P., Hellstrom-Lindberg, E., Bowen, D., Cazzola, M., Stratton, M. R., & Campbell, P. (2012). High throughput targeted gene sequencing in 738 Myelodysplastic Syndromes patients reveals novel oncogenic genes, rare driver mutations and complex molecular signatures with potential impact for patient diagnosis and prognosis in the clinic. Blood, 120(21), [LBA-5]. http://www.bloodjournal.org/content/120/21/LBA-5